KR20200038691A - Anti-oxidant composition comprising the extract of an unripe apple as an effective component - Google Patents
Anti-oxidant composition comprising the extract of an unripe apple as an effective component Download PDFInfo
- Publication number
- KR20200038691A KR20200038691A KR1020180118226A KR20180118226A KR20200038691A KR 20200038691 A KR20200038691 A KR 20200038691A KR 1020180118226 A KR1020180118226 A KR 1020180118226A KR 20180118226 A KR20180118226 A KR 20180118226A KR 20200038691 A KR20200038691 A KR 20200038691A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- green apple
- antioxidant
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 78
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 34
- 235000006708 antioxidants Nutrition 0.000 title abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 235000013376 functional food Nutrition 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 12
- 241000581835 Monodora junodii Species 0.000 claims description 81
- 239000004480 active ingredient Substances 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000002000 scavenging effect Effects 0.000 abstract description 28
- -1 DPPH anion Chemical class 0.000 abstract description 25
- 239000000843 powder Substances 0.000 abstract description 15
- 241000220225 Malus Species 0.000 abstract description 13
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 abstract description 13
- 235000021016 apples Nutrition 0.000 abstract description 8
- 150000001450 anions Chemical class 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 abstract description 5
- 239000006187 pill Substances 0.000 abstract description 3
- 150000001768 cations Chemical class 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 230000000694 effects Effects 0.000 description 12
- 239000000469 ethanolic extract Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000002949 hemolytic effect Effects 0.000 description 9
- 230000036542 oxidative stress Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 206010047531 Visual acuity reduced Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
Abstract
Description
본 발명은 풋사과(unripe apple) 추출물을 유효성분으로 함유하는 항산화 조성물(anti-oxidant composition)에 관한 것으로서, 보다 구체적으로는, 알프스오토메(Alps otome) 품종의 풋사과 추출물을 유효성분으로 함유하는 강력한 DPPH 음이온 소거능, ABTS 양이온 소거능, Nitrite 소거능 및 환원력을 갖는 약학적 조성물, 건강 기능 식품 또는 기능성 화장료 조성물의 용도로서의 항산화 조성물에 관한 것이다.The present invention relates to an anti-oxidant composition containing an unripe apple extract as an active ingredient, and more specifically, a powerful DPPH containing an Alps otome variety of green apple extract as an active ingredient. Anionic scavenging ability, ABTS cation scavenging ability, Nitrite scavenging ability and reducing power, and relates to an antioxidant composition for use in a health functional food or functional cosmetic composition.
산소 호흡을 하는 인체는 산화적 스트레스(oxidative stress)를 피할 수 없으며, 이러한 산화적 스트레스는 활성화된 산소종(reactive oxygen species)의 축척에 의해 나타나게 된다. 즉, 유기물의 대사 과정 중 최종 전자수용체와 산소가 반응하여 물(H2O)로 전환되는 경우에는 세포 독성이 나타나지 않지만, 비정상적인 반응에 의해 과산화수소(H2O2), 슈퍼옥사이드(O2·), 하이드록시 레디칼(OH·) 등이 생성되면, 활성화된 산소종들은 세포 내 높은 라디칼 농도를 유지시켜 단백질 또는 DNA의 손상을 유발하고, 다양한 산화적 스트레스를 유발하여 결국 세포 구조가 손상되고 세포가 기능을 잃거나 변질된다(Choi et al.. 2008. J. Korean Soc. Food Sci. Nutr. 37: 276-281). The oxygen breathing human body cannot avoid oxidative stress, and this oxidative stress is caused by the accumulation of active oxygen species. That is, in the metabolic process of organic matter, when the final electron acceptor and oxygen react and convert to water (H 2 O), cytotoxicity does not appear, but hydrogen peroxide (H 2 O 2 ), superoxide (O2 ·) by abnormal reaction When hydroxy radicals (OH ·) are generated, activated oxygen species maintain a high radical concentration in the cells, causing protein or DNA damage, and inducing various oxidative stresses, resulting in cell structure damage and cell damage. Loss of function or alteration (Choi et al .. 2008. J. Korean Soc. Food Sci. Nutr. 37: 276-281).
또한, 최근의 연구 결과는, 심혈관계 질환과 관련된 혈전 생성에 산화적 스트레스가 직접 관련되어 있으며(Bijak M 등, 2012, Thrombosis Res. 130, 123-128), 산화적 스트레스에 의한 혈관 내 피브리노겐(fibrinogen)의 구조적 변화가 혈전 생성을 촉진하여 혈류 흐름을 저해하여 혈전증을 유발할 수 있음이 알려져 있다(Martinez M 등, 2013. Free Radical Biol. Med. 65, 411-418). 실제 최근의 보고에 따르면, 생체 내의 산화적 스트레스는 발암, 노화, 치매, 염증 및 다양한 심혈관계 질병과 연관되어 있음이 확인되고 있다(Zhang et al., 2013. Chines J. Cancer biotheraphy, 20. 153-158; 조민현, 2014. J. Korean Soc. Pediatr. Nephrol. 18: 7-12: 신정희 외, 2012. 한국산학기술학회논문지 13: 3561-3569). 따라서, 안정성이 확보되면서, 다양한 활성 라디칼을 제거할 수 있는 천연물 성분은 세포의 산화적 스트레스를 억제할 수 있으므로 상당한 도움을 기대할 수 있다고 판단된다. In addition, recent studies have shown that oxidative stress is directly related to thrombus production associated with cardiovascular disease (Bijak M et al., 2012, Thrombosis Res. 130, 123-128), and fibrinogen in blood vessels caused by oxidative stress ( It is known that structural changes of fibrinogen can promote thrombosis and inhibit blood flow, leading to thrombosis (Martinez M et al., 2013. Free Radical Biol. Med. 65, 411-418). In fact, recent reports have confirmed that oxidative stress in vivo is associated with carcinogenesis, aging, dementia, inflammation and various cardiovascular diseases (Zhang et al., 2013. Chines J. Cancer biotheraphy, 20. 153 -158; Cho Min-hyun, 2014. J. Korean Soc. Pediatr. Nephrol. 18: 7-12: Shin Hee Shin et al., 2012. Journal of the Korean Academy of Industrial Science and Technology 13: 3561-3569). Therefore, while stability is secured, it is considered that a natural product component capable of removing various active radicals can suppress oxidative stress of the cell, and thus, it is expected that considerable help can be expected.
현재까지, 다양한 활성 산소종 및 라디칼 물질들을 소거할 수 있는 물질들이 항산화제로 개발되어 있으며, 대표적으로 비타민 C(vitamin C), 비타민 E(vitamin E), BHT(butylated hydroxy toluene) 및 BHA(butylated hydroxy anisole)등이 식품 첨가물, 건강 기능 식품 및 의약품으로 이용되고 있다. 그러나, 강력한 항산화력을 나타내는 합성 항산화제인 BHT 및 BHA의 부작용들이 보고(하현주 등, 2014. Korean J. Culinary Res. 20: 16-26; Choe and Yang, 1982. Korean J. Food Sci. Technol. 14: 283-288)되면서 합성 항산화제를 대치할 수 있는 천연물 항산화제 개발이 필요하게 되었으며, 특히 비타민 C와 같이 열에 약하며 매우 불안정한 물질들을 대치할 수 있는 내열성이 우수한 천연 항산화제 개발이 절실한 상태이다(Ahn et al., 2009. Korean J. Microbiol. Biotechnol. 37: 266-272; Kim et al., 2009. Korean J. Microbiol. Biotechnol. 37: 133-139).To date, various active oxygen species and substances capable of scavenging radical substances have been developed as antioxidants, and are typically vitamin C (vitamin C), vitamin E (vitamin E), butylated hydroxy toluene (BHT) and butylated hydroxy (BHA). anisole) are used as food additives, dietary supplements and medicines. However, side effects of BHT and BHA, synthetic antioxidants showing strong antioxidant power, have been reported (Hyun-Joo Ha, 2014. Korean J. Culinary Res. 20: 16-26; Choe and Yang, 1982. Korean J. Food Sci. Technol. 14 : 283-288) As it became necessary to develop natural antioxidants that can replace synthetic antioxidants, in particular, the development of natural antioxidants with excellent heat resistance to replace very weak and very unstable substances such as vitamin C is in desperate condition ( Ahn et al., 2009. Korean J. Microbiol. Biotechnol. 37: 266-272; Kim et al., 2009. Korean J. Microbiol. Biotechnol. 37: 133-139).
한편, 사과는 맛과 향이 우수한 기호도가 높은 대표적인 과일로서, 우리나라는 사과 재배에 적합한 기온을 보이고, 유효 경사지가 많기 때문에 전체 과수 재배 면적에서 가장 많은 비중을 차지하고 있는 작물이다. 특히, 풋사과는 성숙한 사과에 비해 폴리페놀 성분이 10배 이상 함유되어 있으므로 다양한 생리 활성을 보이는데, 구체적으로, 칼륨과 퀘르세틴이 풍부하여 혈중 콜레스테롤 감소 효과를 나타내며, 노화 방지 및 유해 공기로부터 폐를 보호하는 효과가 알려져 있고, 비타민 B와 C가 풍부하여 피부 건강에도 도움이 될 뿐 아니라, 변비 해소와 항암 및 피로 회복에도 효능이 있는 것으로 알려져 있다.On the other hand, apples are representative fruits with high taste and flavor, and are the most popular crops in the entire fruit-growing area since Korea has a temperature suitable for growing apples and has many effective slopes. In particular, green apples have various physiological activities because they contain 10 times or more of polyphenols compared to mature apples. Specifically, they are rich in potassium and quercetin, which show a blood cholesterol reduction effect, and prevent aging and protect the lungs from harmful air. The effect is known, and it is known that it is rich in vitamins B and C, which not only helps skin health, but also relieves constipation and restores cancer and fatigue.
사과와 관련된 연구는 주로 성숙한 사과를 대상으로 하는 식품 개발 및 사과에 함유된 다양한 생리 활성 물질에 관한 것이며, 풋사과와 관련해서는 풋사과를 식품의 소재로 사용하기 위한 일부 연구에 국한되는데, 예를 들어, 풋사과 분말을 첨가한 식빵의 품질 특성(박봉현, 중앙대학교 의약식품대학원 석사논문, 2017)과 문경 풋사과를 활용한 발효 연구(권순구 등, 한국산업융합학회 논문집, 2016) 등을 들 수 있다. 또한, 풋사과와 관련된 특허 문헌으로는, 예를 들어, 대한민국 등록특허 제10-1194767호 "풋사과 추출물을 함유하는 모공 수축 및 피지 분비 억제용 화장료 조성물", 대한민국 공개특허 제10-2018-0075802호 "풋사과 분말의 제조방법", 대한민국 공개특허 제10-2018-0065352호 "풋사과를 이용한 식초 제조방법" 등이 공개되어 있다. Research related to apples mainly relates to food development targeting mature apples and various bioactive substances contained in apples, and in relation to green apples, it is limited to some studies to use green apples as food ingredients, for example, Quality characteristics of bread with added green apple powder (Bong-Hyun Park, Master's Thesis, Graduate School of Medicine and Food, Chung-Ang University, 2017) and fermentation studies using green apples from Mungyeong (Kwon Sun-Koo et al., Korea Institute of Industrial Convergence, 2016). In addition, as a patent document related to green apple, for example, Republic of Korea Patent Registration No. 10-1194767 "Cosmetic composition for inhibiting pore contraction and sebum secretion containing green apple extract", Republic of Korea Patent Publication No. 10-2018-0075802 Green apple powder manufacturing method ", Republic of Korea Patent Publication No. 10-2018-0065352" green vinegar using green apple "and the like are disclosed.
본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위하여 안출된 것으로서, 본 발명에서 해결하고자 하는 과제는 풋사과 추출물, 보다 구체적으로는, 알프스오토메 품종의 풋사과 추출물을 유효성분으로 함유하는 항산화 조성물을 제공하고자 하는 것이다.The present invention has been devised to solve the problems of the prior art as described above, and the problem to be solved in the present invention is to provide an antioxidant composition containing an green apple extract, and more specifically, an green apple extract of the Alpine automedium as an active ingredient. Is what you want.
상기와 같은 과제를 해결하기 위하여, 본 발명은 알프스오토메 품종의 풋사과 추출물을 유효성분으로 함유하는 암, 치매, 염증 및 심혈관계 질환으로 이루어지는 군으로부터 선택되는 질환의 예방 또는 치료용 약학적 조성물을 제공한다.In order to solve the above problems, the present invention provides a pharmaceutical composition for the prevention or treatment of diseases selected from the group consisting of cancer, dementia, inflammation, and cardiovascular disease, which contains the green apple extract of the Alpine Otto variety as an active ingredient. do.
또한, 본 발명은 알프스오토메 품종의 풋사과 추출물을 유효성분으로 함유하는 항산화용 건강 기능 식품을 제공한다.In addition, the present invention provides an antioxidant health functional food containing the green apple extract of the Alpine Otome variety as an active ingredient.
또한, 본 발명은 알프스오토메 품종의 풋사과 추출물을 유효성분으로 함유하는 항산화용 화장료 조성물을 제공한다.In addition, the present invention provides an antioxidant cosmetic composition containing the green apple extract of the Alpine Otome variety as an active ingredient.
본 발명의 항산화 조성물의 유효성분으로서의 알프스오토메 품종의 풋사과 추출물은, 본 명세서의 실시예를 통해 증명된 바와 같이, 활성 음이온, 활성 양이온 및 nitrite에 대해 매우 강력한 소거능을 나타내며, 우수한 환원력을 동시에 나타낸다. 상기 유효성분은 추출액, 분말, 환, 정 등의 다양한 형태로 가공되어 약학 조성물, 건강 기능 식품 또는 기능성 화장료 조성물 등의 용도로 적용되기에 매우 유용한 발명인 것이다.As an active ingredient of the antioxidant composition of the present invention, the green apple extract of the Alpine automedium variety exhibits a very strong scavenging ability against active anions, active cations and nitrite, and proves excellent reducing power at the same time, as demonstrated through the examples of the present specification. The active ingredients are processed in various forms such as extracts, powders, pills, tablets, etc., and are very useful inventions to be applied to pharmaceutical compositions, health functional foods, or functional cosmetic compositions.
도 1은 알프스오토메 품종의 풋사과를 나타낸 것이고,
도 2는 미야마후지 품종의 풋사과를 나타낸 것이고,
도 3은 진홍 품종의 풋사과를 나타낸 것이고,
도 4는 썸머킹 품종의 풋사과를 나타낸 것이고,
도 5는 홍로 품종의 풋사과를 나타낸 것이다. Figure 1 shows a green apple of the Alps Otome variety,
Figure 2 shows a green apple of the Miyama Fuji variety,
Figure 3 shows the green apple of the crimson varieties,
Figure 4 shows a green apple of the summering varieties,
Figure 5 shows the green apple varieties of green apples.
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 발명자들은 풋사과를 대상으로 항산화 효능을 검정하기 위하여, 다양한 품종의 풋사과를 수확하여 이물질을 제거한 후, 이들을 일정 방법으로 추출물로 조제하고, 상기 추출물의 항산화 활성을 평가하였다. 그 결과, 알프스오토메 품종의 풋사과 추출물에서 매우 강력한 DPPH 음이온 소거능, ABTS 양이온 소거능, Nitrite 소거능 및 환원력을 확인하고, 상기 추출물은 인간 적혈구에 대해 용혈 활성을 나타내지 않으면서도, 열 안정성과 산 안정성이 우수한 특징을 가짐을 확인함으로써 알프스오토메 품종의 풋사과 추출물을 항산화 조성물로 활용하고자 하였다. The inventors of the present invention, in order to test the anti-oxidation efficacy against green apples, harvested green apples of various varieties to remove foreign substances, prepared them as extracts in a certain way, and evaluated the antioxidant activity of the extracts. As a result, Alpine Ottome varieties of green apple extract very strong DPPH anion scavenging ability, ABTS cation scavenging ability, Nitrite scavenging ability and reducing power was confirmed, and the extract does not show hemolytic activity against human red blood cells, but has excellent thermal stability and acid stability. By confirming that it has a try to use the green apple extract of the Alpine Otome variety as an antioxidant composition.
구체적으로, 본 발명자들은 다양한 품종의 풋사과를 이용하여 항산화 조성물을 개발하기 위하여, 국내에서 재배되고 있는 5종의 풋사과 품종을 대상으로 열수 추출물과 에탄올 추출물을 각각 조제하고, 이들 추출물들을 대상으로 다양한 활성 라디칼에 대해 소거능을 평가한 결과, 알프스오토메 품종의 풋사과 추출물에서 강력한 항산화 활성을 나타냄을 확인하였다. 보다 구체적으로, 알프스오토메 품종의 풋사과로부터의 열수 추출물은, 다양한 농도에서 항산화능을 평가한 후, 50% 소거능을 나타내는 RC50을 계산한 결과, DPPH 음이온 소거능, ABTS 양이온 소거능, nitrite 소거능의 RC50이 각각 235.7, 84.6, 44.8μg/ml로 나타났으며, 에탄올 추출물의 경우, 각각 246.2, 105.7 및 79.9μg/ml로 나타나, 여타 품종의 풋사과보다 약 2~4배 강력한 항산화력을 가짐을 확인하였다. 또한, 환원력 평가에서도 0.5mg/ml 농도에서 열수 추출물은 0.639, 에탄올 추출물은 0.677을 나타내어 여타 품종의 풋사과보다 강력한 환원력을 나타내었다. 뿐만 아니라, 상기의 알프스오토메 품종의 풋사과 추출물은 인간 적혈구에 대한 용혈활성을 나타내지 않아 급성독성을 유발하지 않음을 확인하였다.Specifically, the present inventors prepared a hot water extract and an ethanol extract for 5 types of green apple varieties grown in Korea, respectively, in order to develop an antioxidant composition using green apples of various varieties, and various activities were targeted to these extracts As a result of evaluating the scavenging ability of the radicals, it was confirmed that it exhibits strong antioxidant activity in the green apple extract of the Alpine automedium variety. More specifically, the hot-water extract from the putsagwa of Alps Automation varieties, after evaluating the antioxidant activity at various concentrations, as a result of calculating the RC 50 represents the 50% scavenging activity, DPPH anion scavenging activity, ABTS cation scavenging, the nitrite scavenging RC 50 These were 235.7, 84.6, and 44.8 μg / ml, respectively, and the ethanol extracts were 246.2, 105.7, and 79.9 μg / ml, respectively, and were confirmed to have about 2 to 4 times stronger antioxidant power than other types of green apples. . In addition, even in the evaluation of reducing power, at a concentration of 0.5 mg / ml, the hot water extract was 0.639 and the ethanol extract was 0.677, indicating a stronger reducing power than other types of green apples. In addition, it was confirmed that the green apple extract of the above Alpine automedium does not exhibit hemolytic activity against human red blood cells and does not cause acute toxicity.
따라서, 본 발명은 알프스오토메 품종의 풋사과 추출물을 유효성분으로 함유하는 암, 치매, 염증 및 심혈관계 질환으로 이루어지는 군으로부터 선택되는 질환의 예방 또는 치료용 약학적 조성물을 제공한다.Accordingly, the present invention provides a pharmaceutical composition for the prevention or treatment of diseases selected from the group consisting of cancer, dementia, inflammation and cardiovascular disease, which contains the green apple extract of the Alpine Autome variety as an active ingredient.
또한, 본 발명은 알프스오토메 품종의 풋사과 추출물을 유효성분으로 함유하는 항산화용 건강 기능 식품을 제공한다.In addition, the present invention provides an antioxidant health functional food containing the green apple extract of the Alpine Otome variety as an active ingredient.
또한, 본 발명은 알프스오토메 품종의 풋사과 추출물을 유효성분으로 함유하는 항산화용 화장료 조성물을 제공한다.In addition, the present invention provides an antioxidant cosmetic composition containing the green apple extract of the Alpine Otome variety as an active ingredient.
이하에서는, 본 발명의 알프스오토메 품종의 풋사과 추출물의 제조 방법 및 효능 실험 등을 보다 구체적으로 설명한다.Hereinafter, the production method and efficacy test of the green apple extract of the Alpine Otome variety of the present invention will be described in more detail.
본 발명은 다양한 품종의 풋사과를 수확, 이물질을 제거하는 단계; 풋사과를 세절하고 추출물을 조제하는 단계; 풋사과 추출물의 항산화 활성 평가 단계; 및 활성 추출물의 안정성 조사 단계를 포함한다.The present invention harvesting various types of green apples, removing foreign matter; Shredding green apples and preparing an extract; Evaluation of antioxidant activity of green apple extract; And a stability investigation step of the active extract.
본 발명의 "풋사과"는 개화 후 70일 이내의 씨방 및 씨앗이 만들어지지 않은 미성숙 사과를 의미한다. 본 발명에서는 알프스오토메 품종을 비롯하여, 미야마후지, 진홍, 썸머킹 및 홍로 품종의 풋사과를 사용하였다. 상기 "알프스오토메" 품종은 대한민국 국립종자원에 품종명칭등록출원되어 2014년 10월 15일자로 품종명칭등록번호 제03-0001-151호로 등록되어 있는 품종이다. 상기 "미야마후지" 품종은 대한민국 국립종자원에 품종명칭등록출원되어 2005년 3월 16일자로 품종명칭등록번호 제03-0001-80호로 등록되어 있는 품종이다. 상기 "진홍" 품종은 대한민국 국립종자원에 품종명칭등록출원되어 2010년 7월 20일자로 품종명칭등록번호 제03-0001-122호로 등록되어 있는 품종이다. 상기 "썸머킹" 품종은 대한민국 국립종자원에 품종명칭등록출원되어 2011년 3월 23일자로 품종명칭등록번호 제03-0001-124호로 등록되어 있는 품종이다. 상기 "홍로" 품종은 대한민국 국립종자원에 품종명칭등록출원되어 1997년 12월 31일자로 품종명칭등록번호 제03-0001-60호로 등록되어 있는 품종이다. "Foot apple" of the present invention means an immature apple in which seeds and seeds are not made within 70 days after flowering. In the present invention, Alpine Otome varieties, as well as Miyama Fuji, crimson, summering, and Hongro varieties of green apples were used. The "Alps Autome" varieties are varieties registered as a breed name registration number 03-0001-151 on October 15, 2014, and filed with the National Species Resource of Korea. The "Miyama Fuji" varieties are varieties registered as a breed name registration number 03-0001-80 on March 16, 2005, when the breed name registration was filed with the National Species Resource of Korea. The "crimson" varieties are varieties registered as a breed name registration number 03-0001-122 as of July 20, 2010, and filed with the National Species Resource of the Republic of Korea. The "Summer King" varieties are varieties registered as a breed name registration number 03-0001-124 on March 23, 2011. The "Hongro" varieties are varieties registered as a breed name registration number 03-0001-60 as of December 31, 1997, which was filed with the National Species Resource of the Republic of Korea.
본 발명의 조성물에 포함되는 "알프스오토메 품종의 풋사과 추출물"은 알프스오토메 품종의 풋사과를 분쇄하는 단계; 풋사과 분쇄물을 유기용매로 추출하는 단계; 추출액을 0.06mm 이하의 여과망을 사용하여 여과하는 단계; 및 이를 감압농축하는 단계에 의해 수득될 수 있다.The step of crushing the green apple of the Alps automembrane is included in the composition of the present invention. Extracting the green apple crushed material with an organic solvent; Filtering the extract using a filter network of 0.06 mm or less; And concentrating it under reduced pressure.
본 발명에서 사용되는 유기용매는 물(냉수, 열수), 주정, 탄소수 1~4의 무수 또는 함수 저급 알코올(메탄올, 에탄올, 주정, 프로판올, 에틸아세테이트 등), 상기 저급알코올과 물과의 혼합용매 등을 이용할 수 있으며, 열수, 또는 95% 에탄올 추출이 가장 바람직하다.The organic solvent used in the present invention is water (cold water, hot water), alcohol, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms (methanol, ethanol, alcohol, propanol, ethyl acetate, etc.), a mixed solvent of the lower alcohol and water Etc. can be used, and hot water or 95% ethanol extraction is most preferred.
본 발명의 알프스오토메 품종의 풋사과 추출물은 감압 건조, 동결 건조 또는 분무 건조 등과 같은 통상적인 분말화 과정을 거쳐 분말로 제조될 수 있다. 이들은 혈장 내의 다양한 분해 효소에 분해되지 않으며, 100℃의 열처리와 pH 2의 인체 위 내의 pH에서도 활성을 유지한다.The green apple extract of the Alpine automedium variety of the present invention can be prepared as a powder through a conventional powdering process such as vacuum drying, freeze drying or spray drying. They are not degraded by various degrading enzymes in plasma, and they maintain activity even at a heat treatment of 100 ° C and a pH of 2 in the human stomach.
본 발명의 유효성분은 산화적 스트레스와 관련된 질환의 예방 또는 치료용 약학 조성물로 사용될 수 있다. 상기 질환들은, 예를 들어, 암, 치매, 염증 및 심혈관계 질환일 수 있으며, 상기 심혈관계 질환은 심근경색, 가슴 통증, 호흡 곤란, 의식 소실, 뇌졸중, 협심증, 고혈압, 두통, 운동 이상, 감각 이상, 시력 저하, 감슴 통증 등을 들 수 있다.The active ingredient of the present invention can be used as a pharmaceutical composition for the prevention or treatment of diseases associated with oxidative stress. The diseases may be, for example, cancer, dementia, inflammation, and cardiovascular disease, and the cardiovascular disease may be myocardial infarction, chest pain, difficulty breathing, loss of consciousness, stroke, angina, hypertension, headache, dyskinesia, sensation Abnormality, poor vision, and pain in the persimmon.
본 발명의 유효 성분을 포함하는 약학적 조성물은 각각의 사용 목적에 맞게 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁제, 에멀젼, 시럽, 에어로졸 등의 경구 제형, 멸균 주사용액의 주사제 등 다양한 형태로 제형화하여 사용할 수 있으며, 경구 투여하거나 정맥 내, 복강 내, 피하, 직장, 국소 투여 등을 포함한 다양한 경로를 통해 투여될 수 있다.The pharmaceutical composition containing the active ingredient of the present invention is an oral formulation such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, injection of sterile injectable solution according to a conventional method according to each purpose of use. It can be formulated and used in various forms, such as oral administration or intravenous, intraperitoneal, subcutaneous, rectal, and topical administration.
이러한 약학적 조성물에는 추가적으로 담체, 부형제 또는 희석제 등이 더 포함될 수 있으며, 포함될 수 있는 적합한 담체, 부형제 또는 희석제의 예로는 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리쓰리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 비정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 들 수 있다. 또한, 본 발명의 약학적 조성물은 충전제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 더 포함할 수도 있다.The pharmaceutical composition may further include a carrier, excipient or diluent, and examples of suitable carriers, excipients or diluents that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, Starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, amorphous cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil And the like. In addition, the pharmaceutical composition of the present invention may further include a filler, an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, a preservative, and the like.
바람직한 구체예로서, 경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 상기 약학적 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로오스, 락토오스, 젤라틴 등을 혼합하여 제형화한다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 등과 같은 윤활제가 사용될 수도 있다.In a preferred embodiment, solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., such solid preparations comprising at least one excipient in the pharmaceutical composition, for example starch, calcium carbonate, It is formulated by mixing sucrose, lactose, and gelatin. In addition, lubricants such as magnesium stearate and talc may be used in addition to simple excipients.
바람직한 구체예로서, 경구용 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 예시될 수 있으며, 흔히 사용되는 단순 희석제인 물, 액체 파라핀 이외에 여러 가지 부형제, 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.As a preferred embodiment, a liquid preparation for oral use may be exemplified by suspensions, solvents, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients, for example, wetting agents, sweeteners, Fragrances, preservatives, and the like may be included.
바람직한 구체예로서, 비경구 투여를 위한 제제에는 멸균된 수용액제, 비수성용제, 현탁제, 유제, 동결건조제, 좌제 등을 예시할 수 있다. 비수성용제, 현탁제에는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 포함될 수 있다. 주사제에는 용해제, 등장화제, 현탁화제, 유화제, 안정화제, 방부제 등과 같은 종래의 첨가제가 포함될 수 있다.As a preferred embodiment, the formulation for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilizers, suppositories, and the like. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Injections can include conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, preservatives, and the like.
본 발명의 유효 성분은 약제학적으로 유효한 양으로 투여한다. 본 발명에서, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The active ingredient of the present invention is administered in a pharmaceutically effective amount. In the present invention, "a pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is the type of patient's disease, severity, activity of the drug, Sensitivity to the drug, time of administration, route of administration and rate of excretion, duration of treatment, factors including co-drugs, and other factors well known in the medical arts. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with a conventional therapeutic agent, and may be administered single or multiple. Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect in a minimal amount without side effects, which can be easily determined by those skilled in the art.
바람직한 구체예로서, 본 발명의 약학적 조성물에서 유효성분의 유효량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으며, 일반적으로는 체중 ㎏ 당 1 내지 5,000mg, 바람직하게는 100 내지 3,000mg을 매일 또는 격일 투여하거나 1일 1 내지 3회로 나누어 투여할 수 있다. 그러나, 투여 경로, 질병의 중증도, 성별, 체중, 연령 등에 따라서 증감될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.In a preferred embodiment, the effective amount of the active ingredient in the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, and weight, and generally 1 to 5,000 mg per kg of body weight, preferably 100 to 3,000 mg daily Or it can be administered every other day or divided into 1 to 3 times a day. However, since the dosage may be increased or decreased depending on the route of administration, the severity of the disease, sex, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.
본 발명의 약학적 조성물은 다양한 경로를 통하여 대상에 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관 내(intracerebroventricular) 주사에 의해 투여될 수 있다.The pharmaceutical composition of the present invention can be administered to a subject through various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dura mater or intracerebroventricular injection.
본 발명에서 "투여"는 임의의 적절한 방법으로 환자에게 소정의 물질을 제공하는 것을 의미하며, 본 발명의 약학적 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 일반적인 모든 경로를 통하여 경구 또는 비경구 투여될 수 있다. 또한, 본 발명의 조성물은 유효성분을 표적 세포로 전달할 수 있는 임의의 장치를 이용해 투여될 수도 있다.In the present invention, "administration" means providing a predetermined substance to a patient in any suitable way, and the route of administration of the pharmaceutical composition of the present invention is oral or parenteral through all general routes as long as it can reach the target tissue. It can be administered orally. In addition, the composition of the present invention may be administered using any device capable of delivering an active ingredient to target cells.
본 발명에서 "대상"은, 특별히 한정되는 것은 아니지만, 예를 들어, 인간, 원숭이, 소, 말, 양, 돼지, 닭, 칠면조, 메추라기, 고양이, 개, 마우스, 쥐, 토끼 또는 기니아 피그를 포함하고, 바람직하게는 포유류, 보다 바람직하게는 인간을 의미한다.“Subject” in the present invention includes, but is not particularly limited to, humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, mice, rabbits, or guinea pigs, for example. And, preferably, a mammal, more preferably a human.
또한, 본 발명의 건강 기능 식품은 항산화용의 기능성 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 유효성분은 산화적 스트레스와 관련된 질환의 예방 또는 개선의 용도로 사용될 수 있다. 상기 질환들은, 예를 들어, 암, 치매, 염증 및 심혈관계 질환일 수 있으며, 상기 심혈관계 질환은 심근경색, 가슴 통증, 호흡 곤란, 의식 소실, 뇌졸중, 협심증, 고혈압, 두통, 운동 이상, 감각 이상, 시력 저하, 가슴 통증 등을 들 수 있다.In addition, the health functional food of the present invention can be used in various ways, such as antioxidant functional food and beverage. The active ingredient of the present invention can be used for the prevention or improvement of diseases associated with oxidative stress. The diseases may be, for example, cancer, dementia, inflammation, and cardiovascular disease, and the cardiovascular disease may include myocardial infarction, chest pain, difficulty breathing, loss of consciousness, stroke, angina pectoris, hypertension, headache, dyskinesia, sensation Abnormalities, poor vision, chest pain, and the like.
본 발명의 유효성분을 포함하는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.Foods containing the active ingredient of the present invention include, for example, various foods, beverages, gums, teas, vitamin complexes, and dietary supplements, and may be used in the form of powders, granules, tablets, capsules, or beverages. .
본 발명의 유효성분은 일반적으로 전체 식품 중량의 0.01 내지 15중량%로 가할 수 있으며, 건강음료 조성물은 100ml를 기준으로 0.02 내지 10g, 바람직하게는 0.3 내지 1g의 비율로 가할 수 있다.The active ingredient of the present invention can generally be added at 0.01 to 15% by weight of the total food weight, and the health drink composition can be added at a rate of 0.02 to 10g, preferably 0.3 to 1g, based on 100ml.
본 발명의 건강 기능 식품은 지시된 비율로 필수 성분으로서 상기 화합물을 함유하는 것 외에 식품학적으로 허용 가능한 식품보조 첨가제, 예컨대, 천연 탄수화물 및 다양한 향미제 등을 추가 성분으로서 함유할 수 있다. The dietary supplement of the present invention may contain, as an essential ingredient in the indicated proportions, the above compound as an essential ingredient, and may additionally contain, as an additional ingredient, food additives, such as natural carbohydrates and various flavoring additives.
상기 천연 탄수화물의 예로는 포도당, 과당 등의 단당류, 말토오스, 수크로오스 등의 이당류 및 덱스트린, 시클로덱스트린 등의 다당류와 같은 통상적인 당 및 자일리톨, 소르비톨, 에리쓰리톨 등의 당알코올이 있다. Examples of the natural carbohydrate include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and sugars such as xylitol, sorbitol, and erythritol, such as disaccharides such as dextrin and cyclodextrin.
상기 향미제로는 타우마틴, 레바우디오시드 A 또는 글리시르히진과 같은 스테비아 등의 천연 향미제 및 사카린, 아스파르탐 등의 합성 향미제를 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강 기능 식품 100ml당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g을 사용한다. 상기 외에 본 발명의 건강 기능 식품은 여러 가지 영양제, 비타민, 광물, 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강 기능 식품은 천연 과일 주스 및 과일 주스 음료 및 야채 음료 등의 제조를 위한 과육을 함유할 수도 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 본 발명의 유효성분 100중량부 당 0.01 내지 약 20중량부의 범위에서 선택되는 것이 일반적이다.As the flavoring agent, natural flavoring agents such as stevia such as taumatin, rebaudioside A or glycyrrhizine, and synthetic flavoring agents such as saccharin and aspartame can be used. The ratio of the natural carbohydrate is generally used in about 1 to 20 g, preferably about 5 to 12 g per 100 ml of health functional food of the present invention. In addition to the above, the health functional food of the present invention includes various nutrients, vitamins, minerals, synthetic flavoring agents, flavoring agents such as natural flavoring agents, coloring agents and neutralizing agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, and protective colloids It may contain a thickening agent, pH adjusting agent, stabilizer, preservative, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like. In addition, the health functional food of the present invention may contain flesh for the production of natural fruit juice and fruit juice beverage and vegetable beverage. These ingredients can be used independently or in combination. The ratio of these additives is generally selected from 0.01 to about 20 parts by weight per 100 parts by weight of the active ingredient of the present invention.
본 발명의 유효성분은 항산화 용도의 기능성 화장료 조성물로서 사용될 수 있다. 상기 항산화 활성에 따른 효과는, 예를 들어, 색소 침착 개선, 미백 효과, 주름 개선, 피부 탄력 개선, 피부 노화 방지 등을 들 수 있다. The active ingredient of the present invention can be used as a functional cosmetic composition for antioxidant use. The effects according to the antioxidant activity include, for example, improved pigmentation, whitening effect, wrinkle improvement, skin elasticity improvement, and skin aging prevention.
본 발명의 화장료 조성물의 유효성분은 조성물 총 중량에 대해 0.01 내지 50중량%로 포함될 수 있으며, 바람직하게는 0.1 내지 20중량%, 더욱 바람직하게는 1 내지 10중량%이다. 이러한 함량 범위에서 적절한 제형 안정성을 확보할 수 있으며, 목적하는 항산화 효과를 기대할 수 있다.The active ingredient of the cosmetic composition of the present invention may be included in an amount of 0.01 to 50% by weight relative to the total weight of the composition, preferably 0.1 to 20% by weight, more preferably 1 to 10% by weight. Appropriate formulation stability can be secured in this content range, and the desired antioxidant effect can be expected.
본 발명의 상기 조성물은 본 발명의 유효성분 외에도 본 발명의 유효 활성을 저해하지 않는 범위에서 항산화, 피부 노화 방지 및 피부 재생 촉진의 효과를 위한 공지의 천연물 추출물이나 기타 성분을 추가로 포함시켜 이용할 수 있다.In addition to the active ingredients of the present invention, the composition of the present invention can be used by further including a known natural product extract or other ingredients for the effect of antioxidant, anti-aging, and skin regeneration in a range that does not inhibit the effective activity of the present invention. have.
또한, 상기 조성물은 화장료 조성물에 통상적으로 첨가되는 성분들, 예를 들면, 지방 물질, 유기 용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온 봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제와 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제나 담체를 포함하여 특정 제형으로 성형될 수 있다.In addition, the composition is a component commonly added to cosmetic compositions, for example, fatty substances, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, Cosmetics such as fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion blockers and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives or It may be molded into a specific formulation, including adjuvants or carriers commonly used in the field of dermatology.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들면, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 팩, 비누, 계면활성제-함유 클린징, 오일 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 구체적으로는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이, 파우더, 팩트, 립글로즈, 립스틱, 섀도우, 샴푸 및 린스 등의 제형으로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, packs, soaps, surfactants- It may be formulated as containing cleansing, oil and spray, but is not limited thereto. More specifically, flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, powder foundation, emulsion foundation, wax foundation, cleansing cream, cleansing foam, cleansing water, pack, spray, powder, pact, lip gloss It can be prepared in formulations such as rose, lipstick, shadow, shampoo and rinse.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. may be used as a carrier component. You can.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히, 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additionally chlorofluorohydrocarbon, Propellants such as propane / butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대, 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, Fatty acid esters of 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, ethoxylated isostearyl alcohol, suspensions such as polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystals Sex cellulose, aluminum metahydroxide, bentonite, agar or trakant, etc. can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivatives, methyltaurate, sarcosinate, fatty acid amide as a carrier component Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
이하에서는 실시예를 통하여 본 발명을 더욱 상세하게 설명한다. 하기 실시예는 본 발명의 바람직한 일 구체예일 뿐이며, 본 발명의 권리범위가 하기 실시예의 범위로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. The following examples are only preferred embodiments of the present invention, and the scope of the present invention is not limited to the following examples.
[실시예][Example]
실시예 1: 풋사과 품종 및 수확시 특성 Example 1: Green apple varieties and characteristics at harvest
본 실시예에서 사용된 풋사과는 2018년 대한민국 경상북도 청송군 소재 청송군농업기술센터 시험포장에서 재배한 개화 후 70일째 풋사과를 하기 표 1에 기재된 사과 품종별로 입수하였다. The green apple used in this example was obtained by apple varieties listed in Table 1 below on the 70th day after flowering, grown in the test packing of the Cheongsong County Agricultural Technology Center in Cheongsong-gun, Gyeongsangbuk-do, 2018.
[표 1] 풋사과 품종 및 특성[Table 1] Green apple varieties and characteristics
입수된 풋사과의 무게 및 크기를 측정하여 하기 표 2에 나타내었다.Table 2 below shows the weight and size of the obtained green apples.
[표 2] 수확된 풋사과의 품종별 무게 및 크기 [Table 2] Weight and size of each harvested green apple
실시예 2: 풋사과 추출액의 이화학적 특성 비교Example 2: Comparison of physicochemical properties of green apple extract
실시예 1에서 수확된 풋사과 중량의 2 배의 증류수를 가하여 100 ℃에서 1시간 가열하고, 이를 여과하여 풋사과 추출액을 조제하였다. 조제된 풋사과 추출액의 이화학적 특성 및 생차 분석은 하기 표 3에 나타내었다. 미야마후지 품종의 꼭지의 경우, 하기 실시예 3의 열수 추출물을 대상으로 평가하였다.Distilled water of twice the weight of the green apple harvested in Example 1 was added, heated at 100 ° C. for 1 hour, and filtered to prepare a green apple extract. The physicochemical properties and raw tea analysis of the prepared green apple extract are shown in Table 3 below. In the case of the faucet of the Miyama Fuji variety, the hot water extract of Example 3 below was evaluated.
[표 3] 개화 70일째 수확된 풋사과 추출액의 이화학적 특성 및 색차 분석 [Table 3] Physicochemical properties and color difference analysis of green apple extract harvested on the 70th day of flowering
그 결과, 표 3에 나타낸 바와 같이, 개화 70일째 풋사과는 pH 3.4, brix 3.8~4, 산도 0.17~0.58을 나타내었고, 당/산비가 6.5인 진홍 품종이 가장 신맛이 강하였다. 미야마후지 품종의 꼭지는 pH 4.6, brix 1.8, 산도 0.08로 나타났다. 한편, 색차 분석 결과, 명도는 미야마후지와 알프스오토메 품종에서 가장 높았고, 적색도는 진홍 품종에서 가장 높았으며, 황색도는 홍로 품종에서 가장 높았다. 이때, 색차 분석은 Hunter Color Difference meter (Super color SP-80 Colormeter, Tokyo Denshoku Co., Japan)를 이용하여 측정하였으며, 명도(백색 100~0 검정색), 적색도(적색 100~-80 녹색), 황색도(황색 70~-80 검정색)를 측정하였다. 표준백판의 색도는 L값이 92.44, a값이 -0.06, b값이 1.35로 기준을 정하였으며, 시료 당 3회 측정하여 평균값을 구하여 나타내었고 색차(△E)는 다음의 식을 이용하여 계산하였다.As a result, as shown in Table 3, on the 70th day of flowering, the green apple showed pH 3.4, brix 3.8-4, and acidity 0.17-0.58, and the crimson variety with a sugar / acid ratio of 6.5 had the strongest sour taste. The peak of the Miyama Fuji variety was pH 4.6, brix 1.8, and acidity 0.08. On the other hand, as a result of color difference analysis, the brightness was highest in the Miyama Fuji and Alpine Ome varieties, the redness was the highest in the crimson varieties, and the yellowness was the highest in the Hongro varieties. At this time, the color difference analysis was measured using a Hunter Color Difference meter (Super color SP-80 Colormeter, Tokyo Denshoku Co., Japan), brightness (white 100 ~ 0 black), redness (red 100 ~ -80 green), The yellowness (yellow 70-80 black) was measured. As for the chromaticity of the standard white board, the L value was set to 92.44, the a value was -0.06, and the b value was 1.35, and the average value was obtained by measuring three times per sample, and the color difference (△ E) was calculated using the following equation. Did.
실시예 3: 풋사과 추출물의 추출 효율 및 성분 분석Example 3: Extraction efficiency and component analysis of green apple extract
실시예 1의 개화 후 70일째 수확된 풋사과를 품종별로 이물질을 제거하고, 믹서기에 투입하여 풋사과 분쇄물을 조제하고, 이를 대상으로 열수 추출물과 에탄올 추출물을 조제하였다. 열수 추출물은 풋사과 분쇄물에 대해 10배의 증류수를 가하고, 100 ℃에서 1시간씩 3회 반복 추출한 후 추출액을 모아 필터링한 후, 감압 농축하여 분말로 제조하였다. 에탄올 추출물은 풋사과 분쇄물에 대해 10배의 에탄올을 가하고, 상온에서 3회 반복 추출한 후 추출액을 모아 필터링한 후, 감압 농축하여 분말로 제조하였다. The green apples harvested on the 70th day after flowering of Example 1 were removed by type, and put into a blender to prepare green apple crushed products, and hot water extracts and ethanol extracts were prepared as targets. For the hot water extract, 10 times of distilled water was added to the green apple crushed product, and the extract was collected and filtered three times for 1 hour at 100 ° C, filtered and concentrated under reduced pressure to prepare a powder. For the ethanol extract, 10 times of ethanol was added to the green apple crushed product, and the extract was collected and filtered three times at room temperature, filtered, and concentrated under reduced pressure to prepare a powder.
각각의 추출효율 및 추출물의 성분 분석 결과는 표 4에 나타내었다. 성분 분석으로 총 폴리페놀, 총 플라보노이드, 총당 및 환원당 함량을 측정하였다. 총 폴리페놀 함량은 추출 검액 400 μl에 50 μl의 Folin-ciocalteau, 100 μl의 Na2CO3 포화용액을 넣고 실온에서 1시간 방치한 후 725 nm에서 흡광도를 측정하였다. 표준시약으로는 tannic acid를 사용하였다. 총 플라보노이드 함량은 각각의 시료를 18시간 메탄올 교반 추출하고, 여과한 추출 검액 400 μl에 90 % diethylene glycol 4 ml를 첨가하고, 다시 1 N NaOH 40 μl를 넣고, 37 ℃에서 1시간 반응 후 420 nm에서 흡광도를 측정하였다. 표준시약으로는 rutin을 사용하였다. 환원당은 DNS법으로, 총당은 phenol-sulfuric acid법을 이용하여 정량하였다. The results of each extraction efficiency and component analysis of the extracts are shown in Table 4. Total polyphenols, total flavonoids, total sugars, and reducing sugars were determined by component analysis. The total polyphenol content was 50 μl of Folin-ciocalteau, 100 μl of Na 2 CO 3 saturated solution in 400 μl of the extracted sample solution, allowed to stand at room temperature for 1 hour, and absorbance was measured at 725 nm. As a standard reagent, tannic acid was used. The total flavonoid content was extracted by stirring each sample with methanol for 18 hours, adding 4 ml of 90% diethylene glycol to 400 μl of the filtered extraction sample, adding 40 μl of 1 N NaOH again, and reacting at 37 ° C. for 1 hour to 420 nm. Absorbance was measured at. Rutin was used as a standard reagent. The reducing sugar was quantified using the DNS method and the total sugar was phenol-sulfuric acid method.
[표 4] 풋사과 열수 추출물 및 에탄올 추출물의 추출효율 및 유용성분 분석[Table 4] Analysis of extraction efficiency and useful components of green apple extract and ethanol extract
표 4에 나타낸 바와 같이, 열수 추출 효율이 에탄올 추출 효율보다 높았으며, 추출물의 총 플라보노이드, 총당 및 환원당 함량은 유사하게 나타났다. 특히, 총 폴리페놀 함량과 총 플라보노이드 함량은 진홍, 홍로 및 알프스오토메 품종에서 열수 추출물과 에탄올 추출물 모두에서 높게 나타났다.As shown in Table 4, the extraction efficiency of hot water was higher than that of ethanol, and the total flavonoid, total sugar, and reducing sugar contents of the extract were similar. In particular, the total polyphenol content and total flavonoid content were high in both the hot water extract and the ethanol extract in the crimson, hongro, and alpine automation varieties.
실시예 4: 풋사과 추출물의 항산화 활성 Example 4: Antioxidant activity of green apple extract
실시예 3의 풋사과 추출물들의 항산화 활성을 평가하였으며, 추출물을 DMSO(dimethylsulfoxide)에 녹인 후, 적당한 농도로 희석하여 DPPH(1,1-diphenyl-2-picryl hydrazyl) 음이온 라디칼 소거능, ABTS[2,2-azobis (3-ethylbenzo thiazoline-6-sulfonate)] 양이온 라디칼 소거능, nitrite 소거능 및 환원력 측정에 사용하였다. 먼저, DPPH 소거능의 경우 다양한 농도로 희석한 시료 20μl에, 99.5% 에탄올에 용해시킨 2x 10-4M DPPH 용액 380μl를 넣고 혼합하여 37℃에서 30분 동안 반응시킨 후, 516nm에서 microplate reader(Asys Hitech, Expert96, Asys Co., Austria)를 사용하여 흡광도를 측정하였다. DPPH radical 소거능은 시료첨가구와 비첨가구의 백분율로 표시하였다. ABTS 소거능의 경우 7mM ABTS(Sigma Co., USA) 5ml와 140mM potassium persulfate 88ml를 섞은 후, 상온에서 16시간 빛을 차단하여 ABTS 양이온을 형성시켰으며, 이후 이 용액을 414nm에서 흡광도 값이 1.5가 되도록 에탄올로 희석하였다. 조제된 희석용액 190ml와 다양한 농도로 조제된 시료 10ml를 혼합한 후 상온에서 6분간 반응시킨 후 734nm에서 흡광도를 측정하고, 다음의 식에 의해 ABTS radical 소거능을 계산하였다. The antioxidant activity of the green apple extract of Example 3 was evaluated, and the extract was dissolved in dimethylsulfoxide (DMSO), diluted to a suitable concentration, and DPPH (1,1-diphenyl-2-picryl hydrazyl) anion radical scavenging ability, ABTS [2,2 -azobis (3-ethylbenzo thiazoline-6-sulfonate)] It was used to measure cationic radical scavenging capacity, nitrite scavenging capacity and reducing power. First, in the case of DPPH scavenging ability, 380 μl of a 2x 10 -4 M DPPH solution dissolved in 99.5% ethanol was added to 20 μl of samples diluted with various concentrations, mixed and reacted at 37 ° C. for 30 minutes, followed by microplate reader (Asys Hitech at 516 nm) , Expert96, Asys Co., Austria). DPPH radical scavenging activity was expressed as a percentage of sample-added and non-added. In the case of ABTS scavenging ability, 5 ml of 7 mM ABTS (Sigma Co., USA) and 88 ml of 140 mM potassium persulfate were mixed, and the light was blocked for 16 hours at room temperature to form ABTS cations, and the absorbance value was then 1.5 at 414 nm. It was diluted with ethanol. After mixing the prepared dilution solution 190ml and 10ml of the sample prepared at various concentrations and reacting for 6 minutes at room temperature, the absorbance at 734nm was measured, and the ABTS radical scavenging ability was calculated by the following equation.
한편, nitrite 소거능 측정의 경우, 아질산염 용액(1mM)에 시료용액을 가하고, 여기에 0.1N HCl을 가해 pH 1.2로 조정한 후, 37℃에서 1시간 반응시킨 후 Griess reagent(Sigma Co., USA)를 가하고 혼합하였다. 이후, 15분간 실온에서 방치 후 520nm에서 흡광도를 측정하여 잔존 nitrite 양을 측정하였다. nitrite 소거능(%)는 다음의 식에 의해 계산하였다.On the other hand, in the case of nitrite scavenging capacity measurement, a sample solution was added to a nitrite solution (1 mM), and 0.1N HCl was added thereto to adjust the pH to 1.2, followed by reaction at 37 ° C for 1 hour, followed by Griess reagent (Sigma Co., USA) Was added and mixed. Then, after standing at room temperature for 15 minutes, the absorbance was measured at 520 nm to measure the amount of residual nitrite. The nitrite scavenging capacity (%) was calculated by the following equation.
각각의 활성 평가는 각각 3회 반복한 실험의 평균과 편차로 표시하였다.Each activity evaluation was expressed as the mean and the deviation of the experiment repeated 3 times each.
한편, 환원력 평가의 경우, Oyaizu 등의 방법을 변형(안선미 등, 2011. J. Life Sci. 21: 576-583)하여 측정하였다. 에탄올에 용해한 시료 2.5ml에 0.2M sodium phosphate buffer(pH 6.6) 2.5ml와 10% potassium ferricyanide 2.5ml를 첨가하고, 50℃에서 20분간 반응시킨 후, 10% trichloroacetic acid 2.5ml를 첨가하여 반응을 종료하고 4000rpm에서 10분간 원심분리하여 상등액을 회수하였다. 회수한 상등액은 증류수로 2배 희석한 후, 신선하게 조제된 0.1% ferric chloride 용액과 5:1(v/v) 비율로 혼합하고 700nm에서 흡광도를 측정하여 평가하였다. 각각의 항산화력 측정 결과는 표 5에 나타내었다. On the other hand, in the case of evaluating the reducing power, it was measured by modifying the method of Oyaizu et al. To 2.5 ml of the sample dissolved in ethanol, 2.5 ml of 0.2M sodium phosphate buffer (pH 6.6) and 2.5 ml of 10% potassium ferricyanide were added, reacted at 50 ° C for 20 minutes, and then 2.5 ml of 10% trichloroacetic acid was added to terminate the reaction. And the supernatant was recovered by centrifugation at 4000 rpm for 10 minutes. The recovered supernatant was diluted twice with distilled water, mixed with a freshly prepared 0.1% ferric chloride solution in a 5: 1 (v / v) ratio, and evaluated by measuring absorbance at 700 nm. Table 5 shows the results of each antioxidant measurement.
[표 5] 풋사과 추출물의 항산화 활성 평가[Table 5] Evaluation of antioxidant activity of green apple extract
표 5에 나타낸 바와 같이, 품종별 풋사과 추출물을 0.5mg/ml 농도로 조정하여 항산화 활성을 평가한 결과, 열수 추출물 및 에탄올 추출물 모두에서 알프스오토메 품종이 가장 우수한 활성 라디컬 소거능 및 환원력을 나타내었다. 환원력의 경우, 열수 추출물에서는 알프스오토메 = 진홍 > 홍로 > 미야마후지 > 썸머킹의 순으로 우수하였으며, 에탄올 추출물의 경우, 알프스오토메 > 진홍 = 미야마후지 = 홍로 > 썸머킹의 순으로 우수하였다. 한편, 활성 라디컬 소거능의 경우, 모두 강력한 항산화능을 나타내어 항산화력의 정량을 위해, 다양한 농도에서의 각각 추출물의 항산화력을 평가하여 활성 라디컬을 50% 소거하는데 소요되는 농도(RC50)을 결정하였으며, 그 결과는 표 6에 나타내었다. As shown in Table 5, as a result of evaluating antioxidant activity by adjusting the green apple extract for each cultivar to a concentration of 0.5 mg / ml, the Alpine Autome cultivars in both hot water extract and ethanol extract exhibited the best active radical scavenging activity and reducing power. In the case of reducing power, in the order of hot water extract, Alpine Otome = Crimson>Hongro> Miyama Fuji> Summering was superior, and in the case of ethanol extract, Alpine Otome> Crimson = Miyama Fuji = Hongro> Summering was excellent. On the other hand, in the case of active radical scavenging activity, all exhibit strong antioxidant capacity, and for the determination of the antioxidant power, the concentration required to eliminate the active radical by 50% by evaluating the antioxidant power of each extract at various concentrations (RC 50 ) It was determined, and the results are shown in Table 6.
[표 6] 풋사과 추출물의 항산화 활성 평가 (50% 활성 라디컬 소거능을 나타내는 농도 평가)[Table 6] Antioxidant activity evaluation of green apple extract (concentration evaluation showing 50% active radical scavenging activity)
그 결과, DPPH 소거능의 경우, 알프스오토메 품종 풋사과의 열수 추출물에서 235.7μg/ml, 에탄올 추출물에서 246.2μg/ml의 RC50 값을 나타내었고, ABTS 소거능의 경우, 열수 추출물에서 84.6μg/ml, 에탄올 추출물에서 105.7μg/ml의 RC50 값을 나타내었으며, Nitrite 소거능의 경우, 열수 추출물에서 44.8μg/ml, 에탄올 추출물에서 79.9μg/ml의 RC50 값을 나타내어, 알프스오토메 추출물은 여타 품종의 풋사과 추출물과 비교하여 현저히 우수한 항산화력을 나타냄을 확인하였다. 순수 정제된 비타민 C의 DPPH 음이온 소거능, ABTS 양이온 소거능 및 Nitrite 소거능에 대한 RC50 값이 각각 11.5, 5.4 및 18.9μg/ml임을 고려한다면, 알프스오토메 품종의 풋사과 추출물은 다양한 용도의 항산화제로 이용 가능하리라 판단된다.As a result, in the case of DPPH scavenging activity, an RC 50 value of 235.7 μg / ml in the hot water extract of Alpine Otome variety green apple, and 246.2 μg / ml in the ethanol extract, and in the case of ABTS scavenging activity, 84.6 μg / ml in the hot water extract, ethanol The extract showed an RC 50 value of 105.7 μg / ml, and in the case of the Nitrite scavenging ability, the RC 50 value of 44.8 μg / ml in a hot water extract and 79.9 μg / ml in an ethanol extract, the Alpine automembrane extract is a green apple extract of other varieties. Compared with it was confirmed that it shows a remarkably excellent antioxidant power. Considering that RC 50 values for DPPH anion scavenging ability, ABTS cation scavenging ability, and Nitrite scavenging ability of pure purified vitamin C are 11.5, 5.4, and 18.9 μg / ml, respectively, the green apple varieties of green apple extract can be used as antioxidants for various purposes. Is judged.
실시예 5: 풋사과 추출물의 인간 적혈구 용혈 활성Example 5: Human red blood cell hemolytic activity of green apple extract
사과는 오랫 동안 널리 식용된 유해성이 없는 식재료로서 안전성이 확보되어 있다. 본 발명에서는 풋사과 추출물의 급성독성을 평가하기 위해 인간 적혈구 용혈 활성을 평가하였으며, 그 결과는 표 7에 나타내었다. 이때, 용혈 활성은 기존의 보고(김미선 외, 2014. J. Life Sci. 24: 515-521)에 준해 평가하였으며, 간단하게는 PBS로 3회 수세한 인간 적혈구 100μl를 96-well microplate에 가하고 다양한 농도의 시료용액 100μl를 가한 다음 37℃에서 30분간 반응시켰으며, 이후, 반응액을 10분간 원심분리(1,500rpm)하여 상등액 100μl를 새로운 microtiter plate로 옮긴 후 용혈에 따른 헤모글로빈 유출 정도를 414nm에서 측정하였다. 시료의 용매 대조구로는 DMSO(2%)를 사용하였으며, 적혈구 용혈을 위한 실험 대조구로는 Triton X-100(1mg/ml)를 사용하였다. 용혈 활성은 다음의 수식을 이용하여 계산하였다.Apple is a food ingredient that has been widely edible for a long time and has no safety. In the present invention, to evaluate the acute toxicity of the green apple extract, human erythrocyte hemolytic activity was evaluated, and the results are shown in Table 7. At this time, the hemolytic activity was evaluated according to an existing report (Kim Mi-sun et al., 2014. J. Life Sci. 24: 515-521). Simply, 100 μl of human red blood cells washed three times with PBS were added to a 96-well microplate and various After adding 100 μl of the sample solution of the concentration and reacting for 30 minutes at 37 ° C., the reaction solution was centrifuged (1,500 rpm) for 10 minutes to transfer 100 μl of the supernatant to a new microtiter plate, and the degree of hemoglobin outflow due to hemolysis was measured at 414 nm. Did. DMSO (2%) was used as a solvent control of the sample, and Triton X-100 (1 mg / ml) was used as an experimental control for hemolysis of red blood cells. Hemolytic activity was calculated using the following formula.
[표 7] 풋사과 추출물의 인간 적혈구 용혈 활성[Table 7] Human red blood cell hemolytic activity of green apple extract
그 결과 표 7에서 나타낸 바와 같이, 먼저, 대조구로 사용된 DMSO는 적혈구 용혈 활성이 나타나지 않았으며, triton X-100은 1mg/ml 농도에서 적혈구를 100% 용혈시킴을 확인하였다. 한편, 풋사과 추출물은 모든 품종의 열수 추출물과 에탄올 추출물에서 용혈 활성이 전혀 없었다. 따라서, 풋사과 추출물은 별도의 급성 독성 유발의 문제점을 나타내지 않으리라 판단된다. As a result, as shown in Table 7, first, DMSO used as a control did not show red blood cell hemolytic activity, and triton X-100 was confirmed to hemolytically red blood cells 100% at a concentration of 1 mg / ml. On the other hand, the green apple extract had no hemolytic activity in hot water extracts and ethanol extracts of all varieties. Therefore, it is judged that the green apple extract will not exhibit the problem of causing acute toxicity.
실시예 6: 풋사과 추출물의 혈장, 산 및 열 안정성 평가 Example 6: Evaluation of plasma, acid and thermal stability of green apple extract
상기 실시예 3에서 얻은 풋사과 추출물을 대상으로 항산화 활성에 대한 혈장 안정성, 열 안정성 및 산 안정성을 확인하였다. 상기 시료들은 100℃에서 1시간 열 처리, pH 2(0.01M HCl)에서의 1시간 처리, 혈장에서 1시간 처리시에도 항산화 활성의 심각한 감소가 나타나지 않아 높은 안정성을 나타내었다. 따라서, 풋사과 추출물은 소화 흡수 과정 및 식품 제조 과정 중, 우수한 항산화 활성을 유지할 것으로 예상된다.For the green apple extract obtained in Example 3, plasma stability, thermal stability, and acid stability for antioxidant activity were confirmed. The samples exhibited high stability by not showing a significant decrease in antioxidant activity even after 1 hour heat treatment at 100 ° C, 1 hour treatment at pH 2 (0.01M HCl), and 1 hour treatment in plasma. Therefore, the green apple extract is expected to maintain excellent antioxidant activity during the digestion and absorption process and the food manufacturing process.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180118226A KR20200038691A (en) | 2018-10-04 | 2018-10-04 | Anti-oxidant composition comprising the extract of an unripe apple as an effective component |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180118226A KR20200038691A (en) | 2018-10-04 | 2018-10-04 | Anti-oxidant composition comprising the extract of an unripe apple as an effective component |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20200038691A true KR20200038691A (en) | 2020-04-14 |
Family
ID=70291770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180118226A KR20200038691A (en) | 2018-10-04 | 2018-10-04 | Anti-oxidant composition comprising the extract of an unripe apple as an effective component |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20200038691A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210149325A (en) * | 2020-06-02 | 2021-12-09 | (주)중앙타프라 | Functionality Juice Composite Using Apple |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101194767B1 (en) | 2012-04-04 | 2012-10-25 | 고려대학교 산학협력단 | Cosmetic compound containing green apple for pore-minimizing and inhibiting secretion of sebum |
KR20180065352A (en) | 2016-12-07 | 2018-06-18 | 주식회사천년미인 | eparation method of vinegar using an unripe apple |
KR20180075802A (en) | 2016-12-27 | 2018-07-05 | 권태기 | Manufacturing method of unripe apple powder |
-
2018
- 2018-10-04 KR KR1020180118226A patent/KR20200038691A/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101194767B1 (en) | 2012-04-04 | 2012-10-25 | 고려대학교 산학협력단 | Cosmetic compound containing green apple for pore-minimizing and inhibiting secretion of sebum |
KR20180065352A (en) | 2016-12-07 | 2018-06-18 | 주식회사천년미인 | eparation method of vinegar using an unripe apple |
KR20180075802A (en) | 2016-12-27 | 2018-07-05 | 권태기 | Manufacturing method of unripe apple powder |
Non-Patent Citations (2)
Title |
---|
권순구 등, 문경 풋사과를 활용한 발효 연구, 한국산업융합학회 논문집, 2016 |
박봉현, 풋사과 분말을 첨가한 식빵의 품질 특성, 중앙대학교 의약식품대학원 석사논문, 2017 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210149325A (en) * | 2020-06-02 | 2021-12-09 | (주)중앙타프라 | Functionality Juice Composite Using Apple |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101276141B1 (en) | Seed extract of seabuckthorn and method for producing the same | |
KR101771702B1 (en) | Food composition for anti-oxidative activity comprising moringa leaves | |
KR20120024262A (en) | Compositions having antioxidant activity which comprise mixed extracts of natural substances | |
KR20200053014A (en) | Anti-oxidant composition comprising the mixed extract of vegetable natural products having the effect on removal of swelling | |
KR102052523B1 (en) | A composition having anti-bacterial activity comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
JP2016196429A (en) | Nrf2 ACTIVATOR | |
JP6529119B2 (en) | Nrf2-related gene expression promoter | |
KR20200038691A (en) | Anti-oxidant composition comprising the extract of an unripe apple as an effective component | |
KR101004361B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
JP2013184974A (en) | Maillard reaction inhibitor and use thereof | |
JP5976271B2 (en) | Lipase inhibitor and cosmetics, food / beverage composition and pharmaceutical composition containing the same | |
KR20200038720A (en) | Anti-oxidant composition comprising the flower apple extract as an effective component | |
KR100706282B1 (en) | Composition comprising an extract of Trapa japonica Flerov. showing antioxidative effect | |
KR20120073720A (en) | Composition for antiaging comprising the extract of dipterocarpus obtusifolius teijsm. ex miq. as an active ingredient | |
KR102129461B1 (en) | A composition having anti-bacterial activity comprising Selaginella tamariscina extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
KR20190135438A (en) | Antioxidant composition comprising mixture of the extract of Chunggukjang and Modordica charantia | |
KR20220076751A (en) | Anti-oxidant composition comprising the extract of flower apple skk14 as an effective component | |
KR101889431B1 (en) | Pharmaceutical composition for antioxidation comprising black burdock root extracts as an effective component | |
KR101425047B1 (en) | Composition for antioxidant comprising extract or fractions of Rhododendron album Blume as an active ingredient | |
KR102534818B1 (en) | Ambrosia trifida supercritical extract and its use | |
KR102401597B1 (en) | Protectant against neuronal cell death by oxidative stress comprising l-serine and the root extract of angelica gigas as an effective component | |
KR102590758B1 (en) | Antioxidant or anti-inflammatory composition comprising extract of bilberry containing anthocyanidin components | |
KR101425560B1 (en) | Composition for antioxidant comprising extracts or its fractions of Elaeocarpus petiolatus as an active ingredient | |
KR102384358B1 (en) | Antibacterial Composition Comprising Non-aqueous Extract Of Red Ginseng | |
KR102445679B1 (en) | Composition of extracts for antioxidant property containing silk worm pupae and red ginseng |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E601 | Decision to refuse application |